The effect of antiobesity drugs on waist circumference: A mixed treatment comparison

Diabetes, Obesity and Metabolism

Volumn 16, Issue 3, 2014, Pages 237-247

  Chilton, M ^a   Dunkley, A ^a   Carter, P ^a   Davies, M J ^a   Khunti, K ^a   Gray, L J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Lorcaserin; Meta analysis; Obesity; Orlistat

Indexed keywords

LORCASERIN; METFORMIN; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ARTICLE; DRUG EFFECT; DRUG WITHDRAWAL; HUMAN; LIFESTYLE MODIFICATION; META ANALYSIS; OBESITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE;

LORCASERIN; META-ANALYSIS; OBESITY; ORLISTAT;

ANTI-OBESITY AGENTS; BENZAZEPINES; BODY MASS INDEX; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LACTONES; MALE; METFORMIN; OBESITY; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 84893750875     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12198     Document Type: Article

References (34)

1. Withrow D, Alter DA. The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev 2011; 12: 131-141.
2. The NHS Information Centre, Lifestyles Statistics. Statistics on Obesity, Physical Activity and Diet: England, 2013. Available from URL: https://catalogue.ic.nhs.uk/publications/public-health/obesity/obes-phys-acti-diet-eng-2013/obes-phys-acti-diet-eng-2013-rep.pdf. Accessed 9 May 2013.
3. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9: 88.
4. Czernichow S, Kengne AP, Stamatakis E, Hamer M, Batty GD. Body mass index, waist circumference and waist-hip ratio: which is the better discriminator of cardiovascular disease mortality risk?: evidence from an individual-participant meta-analysis of 82 864 participants from nine cohort studies. Obes Rev 2011; 12: 680-687.
5. Pischon T, Boeing H, Hoffmann K et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359: 2105-2120.
6. Jacobs EJ, Newton CC, Wang Y et al. Waist circumference and all-cause mortality in a large US cohort. Arch Intern Med 2010; 170: 1293-1301.
7. Balkau B, Deanfield JE, Després J et al. International Day for the Evaluation of Abdominal Obesity (IDEA). Circulation 2007; 116: 1942-1951.
8. Despres JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001; 322: 716-720.
9. Gray LJ, Cooper N, Dunkley A et al. A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity. Obes Rev 2012; 13: 483-498.
10. Robinson MK. Surgical treatment of obesity-weighing the facts. N Engl J Med 2009; 361: 520-521.
11. Idelevich E, Kirch W, Schindler C. Current pharmacotherapeutic concepts for the treatment of obesity in adults. Ther Adv Cardiovasc Dis 2009; 3: 75-90.
12. Zohrabian A. Clinical and economic considerations of antiobesity treatment: a review of orlistat. Clinicoecon Outcomes Res 2010; 2: 63-74.
13. U.S. Food and Drug Administration. FDA approves Belviq to treat some overweight or obese adults. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm. Accessed 27 June 2012.
14. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011; 2011: 179674.
15. Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatmentcomparisons for technology assessment. Pharmacoeconomics 2008; 26: 753.
16. Jansen JP, Crawford BMA, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008; 11: 956-964.
17. Higgins J, Deeks J. Chapter 7: selecting studies and collecting data. In: Higgins J, Green S eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.1. [updated September 2008]. The Cochrane Collaboration, 2008. Available from URL: www.cochrane-handbook.org.
18. Higgins J, Deeks J, Altman D. Chapter 16: Special topics in statistics. Higgins J, Green S eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.1 [updated September 2008]: The Cochrane Collaboration, 2008. Available from URL: www.cochrane-handbook.org.
19. Song F, Altman DG, Glenny A, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003; 326: 472.
20. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility. Stat Comput 2000; 10: 325-337.
21. Miyatake N, Matsumoto S, Miyachi M, Fujii M, Numata T. Relationship between changes in body weight and waist circumference in Japanese. Environ Health Prev Med 2007; 12: 220-223.
22. de Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J 2007; 28: 850-856.
23. Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-1203.
24. Neovius M, Johansson K, Rössner S. Head-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysis. Obes Rev 2008; 9: 420-427.
25. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721-749.
26. National Collaborating Centre for Chronic Conditions and the Centre for Clinical Practice at NICE. NICE Clinical Guideline 87-Type 2 diabetes. The management of type 2 diabetes, 2011. Available from URL: http://www.nice.org.uk/nicemedia/live/12165/44320/44320.pdf. Accessed 19 June 2012.
27. Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327: 951.
28. Levri KM, Slaymaker E, Last A et al. Metformin as treatment for overweight and obese adults: a systematic review. Ann Fam Med 2005; 3: 457-461.
29. Johansson K, Neovius K, DeSantis SM, Rossner S, Neovius M. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev 2009; 10: 564-575.
30. Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323: 101-105.
31. Sterne JAC, Egger M, Moher D. Chapter 10: addressing reporting biases. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from URL: www.cochrane-handbook.org.
32. AlsNielsen B, Chen W, Gluud CD, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 2003; 290: 921-928.
33. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA's assessment of two drugs for chronic weight management. N Engl J Med 2012; 367: 1577-1579.
34. VIVUS I. VIVUS Receives Formal Decision From CHMP. Available from URL: http://ir.vivus.com/releasedetail.cfm?ReleaseID=714703. Accessed 18 October 2012.